Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
AstraZeneca
McKesson
Colorcon
Express Scripts

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR MIGLITOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Miglitol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00032487 ↗ Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed National Eye Institute (NEI) Phase 3 2000-12-01 This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 ↗ Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed SmithKline Beecham Phase 3 2000-12-01 This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 ↗ Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed VA Office of Research and Development Phase 3 2000-12-01 This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00213070 ↗ Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment Completed Sanwa Kagaku Kenkyusho Co., Ltd. Phase 3 1969-12-31 The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Miglitol

Condition Name

Condition Name for Miglitol
Intervention Trials
Type 2 Diabetes Mellitus 8
Diabetes Mellitus, Type 2 2
Healthy Volunteers 1
Pharmacokinetics of ASP1941 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Miglitol
Intervention Trials
Diabetes Mellitus 11
Diabetes Mellitus, Type 2 10
Diabetes Mellitus, Type 1 1
Pancreatitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Miglitol

Trials by Country

Trials by Country for Miglitol
Location Trials
United States 15
Japan 8
Canada 3
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Miglitol
Location Trials
Tennessee 1
South Carolina 1
Pennsylvania 1
New Jersey 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Miglitol

Clinical Trial Phase

Clinical Trial Phase for Miglitol
Clinical Trial Phase Trials
Phase 3 8
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Miglitol
Clinical Trial Phase Trials
Completed 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Miglitol

Sponsor Name

Sponsor Name for Miglitol
Sponsor Trials
Sanwa Kagaku Kenkyusho Co., Ltd. 6
Canadian Network for Observational Drug Effect Studies, CNODES 3
Canadian Institutes of Health Research (CIHR) 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Miglitol
Sponsor Trials
Other 9
Industry 9
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Mallinckrodt
Dow
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.